p.101 抽出テキスト

ventricular dysplasia/cardiomyopathy patients and family members. Circ Cardiovasc Genet 2015;8:437–446. https://doi.org/10.1161/CIRCGENETICS.114.001003 231. Alfares AA, Kelly MA, McDermott G, Funke BH, Lebo MS, Baxter SB, et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med 2015;17:880–888. https://doi.org/10.1038/gim.2014.205 232. Ingles J, Yeates L, O’Brien L, McGaughran J, Scuffham PA, Atherton J, et al. Genetic testing for inherited heart diseases: longitudinal impact on health-related quality of life. Genet Med 2012;14:749–752. https://doi.org/10.1038/gim.2012.47 233. Friess MR, Marino BS, Cassedy A, Wilmot I, Jefferies JL, Lorts A. Health-related quality of life assessment in children followed in a cardiomyopathy clinic. Pediatr Cardiol 2015; 36:516–523. https://doi.org/10.1007/s00246-014-1042-z 234. Wakefield CE, Hanlon LV, Tucker KM, Patenaude AF, Signorelli C, McLoone JK, et al. The psychological impact of genetic information on children: a systematic review. Genet Med 2016;18:755–762. https://doi.org/10.1038/gim.2015.181 235. Christian S, Somerville M, Taylor S, Atallah J. When to offer predictive genetic testing to children at risk of an inherited arrhythmia or cardiomyopathy. Circ Genom Precis Med 2018;11:e002300. https://doi.org/10.1161/CIRCGEN.118.002300 236. MacLeod R, Beach A, Henriques S, Knopp J, Nelson K, Kerzin-Storrar L. Experiences of predictive testing in young people at risk of Huntington’s disease, familial cardiomyopathy or hereditary breast and ovarian cancer. Eur J Hum Genet 2014;22:396–401. https://doi.org/10.1038/ejhg.2013.143 237. Knight LM, Miller E, Kovach J, Arscott P, von Alvensleben JC, Bradley D, et al. Genetic testing and cascade screening in pediatric long QT syndrome and hypertrophic cardiomyopathy. Heart Rhythm 2020;17:106–112. https://doi.org/10.1016/j.hrthm.2019.06. 015 238. Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 2018;138:1387–1398. https:// doi.org/10.1161/CIRCULATIONAHA.117.033200 239. Marey I, Fressart V, Rambaud C, Fornes P, Martin L, Grotto S, et al. Clinical impact of post-mortem genetic testing in cardiac death and cardiomyopathy. Open Med (Wars) 2020;15:435–446. https://doi.org/10.1515/med-2020-0150 240. Isbister JC, Nowak N, Butters A, Yeates L, Gray B, Sy RW, et al. “Concealed cardiomyopathy” as a cause of previously unexplained sudden cardiac arrest. Int J Cardiol 2021;324:96–101. https://doi.org/10.1016/j.ijcard.2020.09.031 241. Dellefave-Castillo LM, Cirino AL, Callis TE, Esplin ED, Garcia J, Hatchell KE, et al. Assessment of the diagnostic yield of combined cardiomyopathy and arrhythmia genetic testing. JAMA Cardiol 2022;7:966–974. https://doi.org/10.1001/jamacardio.2022. 2455 242. Williams N, Manderski E, Stewart S, Bao R, Tang Y. Lessons learned from testing cardiac channelopathy and cardiomyopathy genes in individuals who died suddenly: a twoyear prospective study in a large medical examiner’s office with an in-house molecular genetics laboratory and genetic counseling services. J Genet Couns 2020;29:293–302. https://doi.org/10.1002/jgc4.1157 243. Isbister JC, Nowak N, Yeates L, Singer ES, Sy RW, Ingles J, et al. Concealed cardiomyopathy in autopsy-inconclusive cases of sudden cardiac death and implications for families. J Am Coll Cardiol 2022;80:2057–2068. https://doi.org/10.1016/j.jacc.2022.09.029 244. Michie S, Bobrow M, Marteau TM. Predictive genetic testing in children and adults: a study of emotional impact. J Med Genet 2001;38:519–526. https://doi.org/10.1136/ jmg.38.8.519 245. Rath A, Weintraub R. Overview of cardiomyopathies in childhood. Front Pediatr 2021; 9:708732. https://doi.org/10.3389/fped.2021.708732 246. Lipshultz SE, Law YM, Asante-Korang A, Austin ED, Dipchand AI, Everitt MD, et al. Cardiomyopathy in children: classification and diagnosis: a scientific statement from the American Heart Association. Circulation 2019;140:e9–e68. https://doi.org/10. 1161/CIR.0000000000000682 247. Kindel SJ, Miller EM, Gupta R, Cripe LH, Hinton RB, Spicer RL, et al. Pediatric cardiomyopathy: importance of genetic and metabolic evaluation. J Card Fail 2012;18: 396–403. https://doi.org/10.1016/j.cardfail.2012.01.017 248. Norrish G, Field E, McLeod K, Ilina M, Stuart G, Bhole V, et al. Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom. Eur Heart J 2019;40:986–993. https://doi.org/10.1093/eurheartj/ehy798 249. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006;296:1867–1876. https://doi.org/10.1001/jama.296.15.1867 250. Shamszad P, Hall M, Rossano JW, Denfield SW, Knudson JD, Penny DJ, et al. Characteristics and outcomes of heart failure-related intensive care unit admissions in children with cardiomyopathy. J Card Fail 2013;19:672–677. https://doi.org/10. 1016/j.cardfail.2013.08.006 251. Pelliccia F, Alfieri O, Calabro P, Cecchi F, Ferrazzi P, Gragnano F, et al. Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: towards the HCM Heart Team. Int J Cardiol 2020;304:86–92. https://doi.org/10.1016/j. ijcard.2020.01.021 252. Law SP, Oron AP, Kemna MS, Albers EL, McMullan DM, Chen JM, et al. Comparison of transplant waitlist outcomes for pediatric candidates supported by ventricular assist devices versus medical therapy. Pediatr Crit Care Med 2018;19:442–450. https://doi. org/10.1097/PCC.0000000000001503 253. Ullmo S, Vial Y, Di Bernardo S, Roth-Kleiner M, Mivelaz Y, Sekarski N, et al. Pathologic ventricular hypertrophy in the offspring of diabetic mothers: a retrospective study. Eur Heart J 2007;28:1319–1325. https://doi.org/10.1093/eurheartj/ehl416 254. Yunis KA, Bitar FF, Hayek P, Mroueh SM, Mikati M. Transient hypertrophic cardiomyopathy in the newborn following multiple doses of antenatal corticosteroids. Am J Perinatol 1999;16:17–21. https://doi.org/10.1055/s-2007-993830 255. Brickman WJ, Silverman BL. Cardiovascular effects of growth hormone. Endocrine 2000;12:153–161. https://doi.org/10.1385/ENDO:12:2:153 256. Monda E, Rubino M, Lioncino M, Di Fraia F, Pacileo R, Verrillo F, et al. Hypertrophic cardiomyopathy in children: pathophysiology, diagnosis, and treatment of nonsarcomeric causes. Front Pediatr 2021;9:632293. https://doi.org/10.3389/fped.2021. 632293 257. Fourey D, Care M, Siminovitch KA, Weissler-Snir A, Hindieh W, Chan RH, et al. Prevalence and clinical implication of double mutations in hypertrophic cardiomyopathy: revisiting the gene-dose effect. Circ Cardiovasc Genet 2017;10:e001685. https:// doi.org/10.1161/CIRCGENETICS.116.001685 258. Kaltenecker E, Schleihauf J, Meierhofer C, Shehu N, Mkrtchyan N, Hager A, et al. Long-term outcomes of childhood onset Noonan compared to sarcomere hypertrophic cardiomyopathy. Cardiovasc Diagn Ther 2019;9:S299–S309. https://doi.org/10. 21037/cdt.2019.05.01 259. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148:671–676.e2. https://doi.org/10.1016/j.jpeds.2005.11.033 260. Linglart L, Gelb BD. Congenital heart defects in Noonan syndrome: diagnosis, management, and treatment. Am J Med Genet C Semin Med Genet 2020;184:73–80. https://doi. org/10.1002/ajmg.c.31765 261. Gelb BD, Roberts AE, Tartaglia M. Cardiomyopathies in Noonan syndrome and the other RASopathies. Prog Pediatr Cardiol 2015;39:13–19. https://doi.org/10.1016/j. ppedcard.2015.01.002 262. Calcagni G, Limongelli G, D’Ambrosio A, Gesualdo F, Digilio MC, Baban A, et al. Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results. Int J Cardiol 2017;245:92–98. https://doi.org/10.1016/j.ijcard. 2017.07.068 263. Lioncino M, Monda E, Verrillo F, Moscarella E, Calcagni G, Drago F, et al. Hypertrophic cardiomyopathy in RASopathies: diagnosis, clinical characteristics, prognostic implications, and management. Heart Fail Clin 2022;18:19–29. https://doi.org/10.1016/j.hfc. 2021.07.004 264. Calcagni G, Adorisio R, Martinelli S, Grutter G, Baban A, Versacci P, et al. Clinical presentation and natural history of hypertrophic cardiomyopathy in RASopathies. Heart Fail Clin 2018;14:225–235. https://doi.org/10.1016/j.hfc.2017.12.005 265. Poterucha JT, Johnson JN, O’Leary PW, Connolly HM, Niaz T, Maleszewski JJ, et al. Surgical ventricular septal myectomy for patients with Noonan syndrome and symptomatic left ventricular outflow tract obstruction. Am J Cardiol 2015;116:1116–1121. https://doi.org/10.1016/j.amjcard.2015.06.037 266. Hemmati P, Dearani JA, Daly RC, King KS, Ammash NM, Cetta F, et al. Early outcomes of cardiac surgery in patients with Noonan syndrome. Semin Thorac Cardiovasc Surg 2019;31:507–513. https://doi.org/10.1053/j.semtcvs.2018.12.004 267. Moran AM, Colan SD. Verapamil therapy in infants with hypertrophic cardiomyopathy. Cardiol Young 1998;8:310–319. https://doi.org/10.1017/S1047951100006818 268. van der Ploeg AT, Reuser AJ. Pompe’s disease. Lancet 2008;372:1342–1353. https:// doi.org/10.1016/S0140-6736(08)61555-X 269. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68:99–109. https://doi.org/10.1212/01.wnl.0000251268.41188. 04 270. Tanaka M, Ino H, Ohno K, Hattori K, Sato W, Ozawa T, et al. Mitochondrial mutation in fatal infantile cardiomyopathy. Lancet 1990;336:1452. https://doi.org/10.1016/0140- 6736(90)93162-I 271. Holmgren D, Wahlander H, Eriksson BO, Oldfors A, Holme E, Tulinius M. Cardiomyopathy in children with mitochondrial disease; clinical course and cardiological findings. Eur Heart J 2003;24:280–288. https://doi.org/10.1016/S0195- 668X(02)00387-1 272. Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005;352:362–372. https://doi.org/10.1056/NEJMoa033349 273. Ansong AK, Li JS, Nozik-Grayck E, Ing R, Kravitz RM, Idriss SF, et al. Electrocardiographic response to enzyme replacement therapy for Pompe disease. Genet Med 2006;8:297–301. https://doi.org/10.1097/01.gim.0000195896.04069.5f 274. Schoser B, Attarian S, Borges J, Bouhour F, Chien Y, Choi Y, et al. Efficacy and safety results of the avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients. Eur J Neurol 2021;28:68–68. 275. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 2010;362:1396–1406. https://doi.org/10.1056/NEJMoa0909859

ESC Guidelines                                                                                                                                                                                          3603

Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026